What Is Kanna? The Complete Guide to Sceletium tortuosum (2026)

Kanna is the common name for Sceletium tortuosum, a low-growing, creeping succulent in the Aizoaceae family (the same broad family as the ice plants and "living stones"). It's native to the semi-arid regions of South Africa, particularly the Karoo, where it survives long dry spells by storing water in its fleshy leaves. The genus name Sceletium comes from the skeletal leaf veins that remain visible as the leaves dry — a small botanical detail that gives the plant its look.

You'll see several names used more or less interchangeably: kanna, channa, and kougoed. The last literally relates to chewing — the traditional way the plant is consumed — and that single fact tells you most of what you need to know about how it was historically used.

Kanna has one of the longest documented histories of any mood-acting botanical. The Khoisan peoples of southern Africa — the San and Khoekhoe — chewed and fermented the plant long before Europeans arrived, using it to blunt hunger, ease tension, and steady the mind on long treks. The plant was first introduced to Europeans around 1662, when Dutch colonial records noted its use.

The traditional preparation is not just raw chewing. The harvested plant is bruised and packed to ferment — a process called making kougoed — which is thought to shift the plant's alkaloid balance and reduce harshness. The fermented material is then dried and chewed, brewed as a tea, or used as a snuff. This is a genuine traditional-knowledge lineage, and any honest account of kanna credits the Khoisan as its source; reputable suppliers increasingly emphasize ethical, community-partnered sourcing for exactly that reason.

This is where kanna earns its reputation. According to Harvey et al. (2011, Journal of Ethnopharmacology), kanna acts through a dual mechanism: it is both a serotonin-reuptake inhibitor (SRI) — broadly the same class of action as an SSRI antidepressant — and a PDE4 inhibitor. The active compounds are a group of mesembrine-type alkaloids: mesembrine is the most potent at the serotonin transporter, while mesembrenone is the strongest PDE4 inhibitor.

That combination is why kanna doesn't fit neatly next to the other legal botanicals. Kava works mainly on GABA for relaxation; CBD acts on the endocannabinoid system; kratom hits opioid receptors. Kanna's serotonin-plus-PDE4 profile is its own thing — and it's also the reason for the single most important safety caution below.

Framed experientially — not as medical outcomes — the effects most commonly described are a mild mood lift, a sense of lowered stress or tension, easier sociability and talkativeness, and for some a clearer, more present focus. The experience is usually subtle rather than dramatic; people often describe "the edge coming off" rather than an obvious high.

Effects appear to be dose-dependent: lower doses tend to feel more uplifting and lightly stimulating, while higher doses are more often described as calming or even sedating. This dose-response pattern comes from traditional use and user reports rather than a formal dose-ranging clinical trial, so treat it as a useful rule of thumb, not a proven curve. Onset is roughly 15–40 minutes for chewed or sublingual forms and longer for capsules, with effects typically lasting one to three hours.

Kanna is sold in five main formats, and the right one depends mostly on how much control and convenience you want. The table below is a quick map; doses are general guidance, not a prescription.

As a calibration point, roughly 25mg of Zembrin standardized extract ≈ 50mg of dry raw plant ≈ ~100–200µg of total alkaloids. Concentrates like 100:1 powders or high-mesembrine MT55 are far stronger by weight, which is exactly why a milligram scale matters once you leave the pre-dosed gummy/capsule lane.

In the United States, kanna is federally uncontrolled and legal, sold as a botanical dietary supplement. It is not FDA-approved to treat, cure, or prevent anything. It's legal in most other countries as well and is not scheduled under any UN drug convention.

The one frequently-cited exception is Louisiana, which is commonly reported to restrict Sceletium tortuosum to ornamental (non-consumption) use — verify the current statute before relying on that. As always, supplement legality can change, so check your local rules.

The short answer is that the available evidence is reassuring but limited. A 3-month placebo-controlled trial of standardized kanna in 37 adults (Nell et al. 2013) found both 8mg and 25mg daily doses were well-tolerated, with no significant changes in vitals, ECG, blood chemistry, or weight versus placebo. Reported side effects across studies and user reports are generally mild — headache, nausea (especially at higher doses), appetite loss, and occasional dizziness or drowsiness.

The one caution that genuinely matters: because kanna raises serotonin much as an SSRI does, it should not be combined with SSRIs, SNRIs, MAOIs, or other serotonergic medications without medical advice, and it's best avoided in pregnancy. This is a precaution based on how kanna works — documented serotonin-syndrome cases from kanna are essentially absent — but it's the rule worth taking seriously.

Finally, the broader caveat that runs through everything here: the human clinical base is small (n=16–37), short, mostly conducted on the single patented Zembrin extract, and partly industry-linked. Kanna is promising and well-tolerated in the studies we have, but "promising and early" is the accurate description — not "proven." None of this is medical advice; talk to a clinician about your own situation.